The Glutamate Side of Things

Some readers have suggested that since we have discovered so many ways to treat the GABAA dysfunctions common in autism, it is time to look at the glutamate side of things. Glutamate is the main excitatory neurotransmitter and has to be in balance with the opposing influence of GABA.

The chart below is really a summary of what has already been covered in this blog.  To newcomers it will look complicated, to regular readers it is just bringing together everything we have already covered, even those tauopathies appear. Tau protein tangles appear in Alzheimer’s and some autism.
Glutamate excitoxicity is what happens when things go really wrong, for example in a severe autistic regression.  I doubt you could be in a permanent state like this.



I am beginning to wonder is my son’s summer time raging, though triggered by allergy, develops to a so-called glutamatergic storm.  It fades to nothing  by using a Cav1.2 channel blocker, which does indeed stop those allergy mast cells de-granulating, but it stops the calcium influx in the above chart.  Existing dysfunction in Cav1.2 and Cav1.4 puts you at risk of excitotoxicity.
The oxidative damage to mitochondria causes lipid peroxidation and in particular the 4-HNE produced will cause tau protein, from a recent post and Alzheimer’s, to produce tau tangles, a damaging feature of so-called tauopathies.
The nitrosative stress in particular damages the production of the Complex 1 enzyme leading to mitochondrial disease/dysfunction. The damaging peroxynitrates can be quenched using high doses of calcium folinate. Oxidative stress and the reduced level of GSH can be treated with antioxidants like NAC and ALA.  

Reduced reuptake of glutamate, known to be caused by elevated TNF-α and immune dysfunction, is treatable via upregulating the GLT-1 transporter (beta-lactam antibiotics, riluzole and bromocriptine).
Elevated BDNF is a biomarker of autism and unfortunately this increases the chances of glutamate excitotoxicity.
An inactivated GABA switch that leaves neurons immature, will result in GABA acting excitatory rather than inhibitory, this itself can trigger of glutamate excitotoxicity. Use bumetanide.
Some types of autism feature NMDA hyper-function, this is treatable.  A deviation of NMDA function in either direction (hypo or hyper) leads to autism, but you need to know which way it is, to treat it.

It is also possible to have over/under expression of NMDA receptors.




Comments

Post a Comment

Popular posts from this blog

Gingerols and Statins (as Farnesyltransferase inhibitors) for RASopathies and Some Autism

Image
Today’s post was driven by another attempt not to take a statin. Statins are among the world’s most prescribed, and yet most maligned, drugs.  Hundreds of millions of people take a statin drug every day to lower their cholesterol, but a small, vocal minority complain about muscle pains, memory loss and even type 2 diabetes. Since my Polypill is evidently a therapy, and not a cure, for autism, the odds are that it will be needed life-long.  Regardless of the apparent lack of side-effects, nobody should be taking drugs/supplements that are not really needed.  Atorvastatin (Lipitor/Sortis) is part of my Polypill for the type of autism affecting Monty, aged 11, with ASD. Every time I stop the statin part of my Polypill therapy, I end up starting it again after only a one day break.  I notice all sorts of little behavioral changes that I really do not want to see.    These changes involve loss of initiative, flexibility and motivation.  I really do not see...
Read more

Bumetanide Dosage & Effectiveness in Autism & Asperger's

Image
The clinical trial of Bumetanide in autism, published in 2012, was what triggered my interest in using drugs to treat autism. A randomised controlled trial of bumetanide in the treatment of autism in children In that trial on children aged 3-11 years, the dosage used was 1mg a day, split in two doses. In my trial, I found 1mg in the morning effective, while splitting the dose rendered it ineffective.   I was surprised to hear that the French researchers find the treatment effective in 90% of cases of autism, including Asperger’s.   The reason is that while Monty, now aged 10 with ASD, is a responder, it seems that most people I know who have tried it have not responded.   O nly one did respond, and that was when the father upped the dosage. Now I hear that Lemmonier’s standard dosage has doubled to 2mg a day, with 1mg in the morning and 1mg at 5pm.  He tries for three months, before assuming the drug to be ineffective. So to anyone who tried Bumetanide without succes...
Read more

GABA, bumetanide, ketogenic diet, channelopathies, histamine … and all other things autism

Image
A Guest Post by UK Charity Treating Autism If you are a reader of this blog and interested in all things autism, especially those things regularly discussed here, you may want to find yourself in London on the weekend of 18-19 June, attending a conference organised by a UK charity Treating Autism. The location is Brunel University campus - a stone’s throw from Heathrow airport, or a fun tube ride from Eurostar St Pancras station. If you can only attend one day make sure it is Sunday 19 th , as this day will feature presentations on most promising treatment approaches in autism including the one on bumetanide for autism titled ‘ Reducing symptoms of autism by addressing dysfunctional GABA: A chloride concentration story’ by none other than Dr Lemonnier himself. Prof Dr Athanasios Evangeliou of Papageorgiou Hospital Thessaloniki will be giving not one but two presentations: ‘Autism, epilepsy and metabolic disorders’ (am) and ‘ “ Alternative” treatments for Autism in mainstream clinical s...
Read more